MENU
+Compare
INMB
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$6.45
Change
-$0.27 (-4.02%)
Capitalization
143.01M

INMB INmune Bio Forecast, Technical & Fundamental Analysis

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INMB with price predictions
Jan 14, 2025

INMB in +23.40% Uptrend, growing for three consecutive days on January 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INMB advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on INMB as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for INMB just turned positive on December 31, 2024. Looking at past instances where INMB's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

INMB moved above its 50-day moving average on January 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INMB crossed bullishly above the 50-day moving average on January 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for INMB moved out of overbought territory on January 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INMB broke above its upper Bollinger Band on January 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INMB entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.698) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). INMB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). INMB's P/S Ratio (3333.333) is very high in comparison to the industry average of (263.573).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INMB is expected to report earnings to fall 8.15% to -55 cents per share on February 27

INmune Bio INMB Stock Earnings Reports
Q4'24
Est.
$-0.55
Q3'24
Missed
by $0.08
Q2'24
Beat
by $0.13
Q1'24
Missed
by $0.08
Q4'23
Missed
by $0.04
The last earnings report on October 31 showed earnings per share of -60 cents, missing the estimate of -51 cents. With 379.99K shares outstanding, the current market capitalization sits at 143.01M.
A.I. Advisor
published General Information

General Information

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

INMB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with ABCL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
-4.02%
ABCL - INMB
36%
Loosely correlated
+1.02%
RARE - INMB
34%
Loosely correlated
-2.08%
PRME - INMB
34%
Loosely correlated
+0.70%
SAGE - INMB
34%
Loosely correlated
+1.58%
ATOS - INMB
33%
Loosely correlated
-2.47%
More